Phase I/II Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs AAV1 FS344 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 28 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Sep 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.